Navigation Links
Biosimilars of Rituxan, MabThera, Herceptin and Erbitux will Erode $8.2 Billion in U.S. and European Sales in 2018
Date:9/15/2009

WALTHAM, Mass., Sept. 15 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, forecasts that U.S. and European (France, Germany, Italy, Spain and U.K.) sales of Roche/Biogen Idec's Rituxan/MabThera, Bristol-Myers Squibb/Merck's Erbitux and Roche's Herceptin will peak at almost $16 billion in 2014, before falling to roughly $10 billion in 2018. Biosimilars of these three branded agents are forecasted to erode $8.2 billion in U.S. and European sales in 2018 but they are expected to capture only $4.6 billion in sales due to their lower prices.

"Biosimilars of the five brands covered in this report (Rituxan/MabThera, Erbitux, Herceptin, Amgen's Neupogen and Neulasta) will erode $34.3 billion in brand sales during our 2008-2018 forecast period across the U.S. and Europe and save health care systems $17.3 billion in the process," stated Michael Malecki, Ph.D., analyst and product manager at Decision Resources.

The new special report entitled Biosimilars: G-CSFs and Monoclonal Antibodies in Oncology also finds that oncologists are expected to demand clinical data for biosimilars demonstrating equivalence in multiple subpopulations. That is, although a biosimilar may be labeled for use in multiple subpopulations, oncologists will not feel comfortable prescribing a biosimilar without clinical validation.

Over time, oncologists are expected to become more comfortable using biosimilars in subpopulations and/or indications for which the reference product is approved but not clinically validated. In order to slow the growth of physician comfort in this regard, makers of branded biologics should emphasize the proven efficacy records of their agents and the importance of using a fully validated therapy for patients with life-threatening disease.

"Although surveyed oncol
'/>"/>

SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. GPhA Statement on Introduction of H.R. 1548, The Pathway for Biosimilars Act
2. Decision Resources White Paper Discusses Increasing Reality of Biosimilars and their Impact on Biologics Market
3. Broad Stakeholder Coalition Concludes that the Pathway for Biosimilars Act Fails to Ensure Timely Access to Safe, Affordable Biogeneric Medicines for Patients
4. Routine Testing Would Improve Herceptin Use in Breast Cancer
5. Mathematical modeling predicts response to Herceptin
6. If Herceptin is Approved in Combination With Other Emerging Therapies it Will be in a Position to Retain Patient Share From Tykerb/Tyverb for the Treatment of HER2-Positive Breast Cancer
7. Xeloda(R), Taxotere(R) and Herceptin(R) Combination Study Suggests Clinical Benefit in Invasive Breast Cancer with Shortened Treatment Cycle
8. Herceptin helps women with multiple chromosomes containing HER2 gene, study finds
9. Erbitux May Help Some With Colorectal Cancer
10. Use of Avastin and Erbitux in the Adjuvant Setting and Launches of Emerging Agents Will Drive the Colorectal Cancer Drug Market to $7.8 Billion in 2017
11. Erbitux Works Well for Two-Thirds of Colon Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... January 22, 2015 The Incredible Bulk is ... Pakulski to increase lean muscle by up to 30lbs in ... the attention of HealthyandFitZone.com’s Stan Stevenson, prompting an investigative review. ... is a step-by-step, scientific diet formula that allows the body ...
(Date:1/22/2015)... New York (PRWEB) January 22, 2015 The ... ) in the U.S. District Court, Southern District of West ... Bard, Inc. in that proceeding’s first bellwether trial. In an ... for a new trial after finding that C.R. Bard had ...
(Date:1/22/2015)... released a new blog post explaining the main features of ... Auto insurance quotes help many drivers find the best coverage ... an agent or visit an agency for price information. These ... http://autocarinsurancebest.com/ . , Every business who relies heavily on transportation ...
(Date:1/22/2015)... 2015 A study recently published ... journal Medicine & Science in Sports & Exercise ... help reduce gastrointestinal (GI) problems associated with physical ... in the double-blind, placebo-controlled study took 10 grams ...
(Date:1/22/2015)... Four years since the release of their debut recording Love ... of Avasa & Matthew Love – the duo are pleased to ... through White Swan Records on February 24, 2015. , THE ROAD ... available to all of us to walk out of the mire ...
Breaking Medicine News(10 mins):Health News:The Incredible Bulk: Review Examining Ben Pakulski’s Brand New Bulking Muscle Building Diet Program Released 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 4Health News:Commercial Auto Insurance Provides Several Important Features! 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 3Health News:THE ROAD by Avasa & Matthew Love -- A New Album 2Health News:THE ROAD by Avasa & Matthew Love -- A New Album 3Health News:THE ROAD by Avasa & Matthew Love -- A New Album 4
... maker of the HiArt treatment system for advanced radiation therapy, announced ... linear accelerator manufacturer Chengdu Twin Peak Accelerator Technology Inc., based in ... ... EON) November 4, 2008 -- A linear accelerator (linac) is ...
... 4 With the possibility of,a failed ceasefire ... humanitarian situation in the Democratic Republic of Congo,(DRC), ... of therapeutic food to thousands of displaced civilians ... this crisis could develop into a full-blown catastrophe,if ...
... be Held at 8 a.m. EST -, SHENZHEN, ... (NYSE: NPD ) ("China Nepstar" or the "Company"), ... of directly operated,stores, announced today that the Company will ... before the market opens on,Wednesday, November 26, 2008., ...
... CHAPEL HILL, N.C., Nov. 4 As ... product development,opportunities, fixed-dose combination (FDC) products have ... In an effort to better,understand the development ... a,recent study was conducted by Best Practices, ...
... bond between doctor, parents opens way to discuss habits, ... News) -- Parents are willing to discuss their drinking ... parents for alcoholism and refer them for evaluation or ... commitment to child health, frequent interactions with parents, and ...
... Administrator Sentenced to 70 Months for $11 million ... Ronald,Harris, 58, was sentenced today to 84 months ... was sentenced today to 70 months in,prison for ... scale,HIV infusion fraud schemes, Acting Assistant Attorney General ...
Cached Medicine News:Health News: TomoTherapy Completes Acquisition of Linear Accelerator Manufacturer in China 2Health News:International Medical Corps Continues Delivering Emergency Relief in Democratic Republic of Congo as Potential for Renewed Fighting Threatens to Deepen Crisis 2Health News:China Nepstar Chain Drugstore to Announce Third Quarter 2008 Financial Results on November 26 2Health News:China Nepstar Chain Drugstore to Announce Third Quarter 2008 Financial Results on November 26 3Health News:New Study Provides Benchmarks for Fixed-Dose Combination (FDC) Drug Development 2Health News:Pediatricians Could Help Screen for Alcohol Abuse in Home 2Health News:Miami Physician Sentenced to 84 Months in Prison for $26.2 Million Medicare Fraud 2Health News:Miami Physician Sentenced to 84 Months in Prison for $26.2 Million Medicare Fraud 3
(Date:1/23/2015)... ANGELES , Jan. 23, 2015 A lot of ... best methods for treating  certain illnesses, injuries, or conditions. As ... replace previous treatment methods with ones that they consider to ... hernias, there is not one textbook method of treatment that ...
(Date:1/23/2015)... Jan. 23, 2015  The Partnership to Fight Chronic Disease (PFCD) released ... care leaders and a new study analyzing the impact of increased ... a nationwide coalition working to educate policy makers and the public ... Capitol was focused on how the Iowa ...
(Date:1/23/2015)... 2015  Northwest Biotherapeutics, Inc. (NASDAQ: NWBO )("NW Bio"), ... operable and inoperable solid tumor cancers, announced today that CEO ... Annual Phacilitate Immunotherapy Forum in Washington D.C. ... take place on January 26 at 10:30 a.m. EST at ...
Breaking Medicine Technology:No One-Size-Fits-All Remedy for Hernia Correction 2New research shows Iowa health exchange would benefit from improvements 2New research shows Iowa health exchange would benefit from improvements 3NW Bio To Present At The 7th Annual Phacilitate Immunotherapy Forum 2NW Bio To Present At The 7th Annual Phacilitate Immunotherapy Forum 3
... , , PHOENIX, ... published two new publications on hormone therapies and their effects on ... , Cardiovascular disease caused by atherosclerosis, or the build-up ... of American women--40% of total deaths--and the rate of mortality is ...
... OMER and MIGDAL HA,EMEK, Israel, August 3 ,Medigus ... visualization,medical devices, and Tower Semiconductor, Ltd. (Nasdaq: ... today announced successful,sampling of a new CMOS imager that ... its new medical devices camera; the smallest of its,kind ...
Cached Medicine Technology:TWO NEW KLRI PEER-REVIEWED PUBLICATIONS: Hormone Therapy May Reduce Atherosclerosis in Women Close to Menopause; Growth Hormone May Increase Risk of Diabetes, Improve Lipid Profile in Men 2TWO NEW KLRI PEER-REVIEWED PUBLICATIONS: Hormone Therapy May Reduce Atherosclerosis in Women Close to Menopause; Growth Hormone May Increase Risk of Diabetes, Improve Lipid Profile in Men 3Medigus and Tower Semiconductor Announce World's Smallest Medical Video Camera Based on Advanced CMOS Image Sensor 2Medigus and Tower Semiconductor Announce World's Smallest Medical Video Camera Based on Advanced CMOS Image Sensor 3Medigus and Tower Semiconductor Announce World's Smallest Medical Video Camera Based on Advanced CMOS Image Sensor 4
Intera 3.0T is the most compact high-field clinical whole-body MR system in the world, bringing 3.0T capabilities "out of the tunnel" and into the light of an open, patient-friendly design....
... are designed to provide distraction of ... disc removal, endplate preparation, and insertion ... of several Vertebral Spreaders, Intradiscal Wedges, ... Vertebral Body Positioner. Used in ALIF ...
... is a point-of-care system designed for the ... to as Platelet Rich Plasma - PRP) ... small sample of blood. The Symphony II ... which are found in the platelets. The ...
... gel has an extensive base of experience ... platelet gel. When concentrated autologous platelets are ... structural and functional changes involved in coagulation ... a number of factors including serotonin, fibronectin, ...
Medicine Products: